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AIM: To re-examine whether hepatic vein thrombosis
(HVT) (classical Budd-Chiari syndrome) and hepatic
vena cava-Budd Chiari syndrome (HVC-BCS) are the
same disorder.
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D, Xu Y, Wu Fy, Lee BB and Li LS conducted the research; Shin
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and dataset available from the corresponding author at young.
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METHODS: A systematic review of observational
studies conducted in adult subjects with primary BCS,
hepatic vein outflow tract obstruction, membranous
obstruction of the inferior vena cava (IVC), obliterative
hepatocavopathy, or HVT during the period of January
2000 until February 2015 was conducted using the follow
ing databases: Cochrane Library, CINAHL, MEDLINE,
PubMed and Scopus.
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work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited and
the use is non-commercial. See: http://creativecommons.org/
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RESULTS: Of 1299 articles identified, 26 were included
in this study. Classical BCS is more common in women
with a pure hepatic vein obstruction (49%-74%). HVCBCS is more common in men with the obstruction
often located in both the inferior vena cava and hepatic
veins (14%-84%). Classical BCS presents with acute
abdominal pain, ascites, and hepatomegaly. HVC-BCS
presents with chronic abdominal pain and abdominal
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lexicon now includes a myriad of ambiguous terms or
eponyms: Budd’s disease, Chiari’s disease, Chiari’s synd
rome, Rokitansky’s disease, von Rokitansky disease,
Hepatic vein outflow tract obstruction, membranous
obstruction of the IVC, obliterative hepatocavopathy,
Hepatic vena cava disease, Budd-Chiari syndrome with
[6-8]
occlusion of hepatic vein, or hepatic vein thrombosis .
These eponyms have been used at some point during
the course of further discovery; this disarray of terms,
some of which are unclear and nonspecific, reflects not
only the heterogeneous presentation of BCS, but also
the possibility of distinct entities within this syndrome.
The currently accepted definition of primary BCS is
hepatic outflow obstruction regardless of the cause or
[6,9]
level of obstruction . The obstruction can range from
the small hepatic veins to the orifice of the IVC into the
right atrium. Sinusoidal obstruction syndrome is excluded
[6,9]
from this definition . Secondary BCS is defined as a
hepatic venous outflow obstruction due to compression
or invasion by extravascular lesions, including benign or
malignant diseases such as abscesses, hepatocellular
carcinomas, and renal cell carcinomas, or secondary to
[6,9]
cardiac or pericardial diseases .
[4]
In 1998, Okuda et al proposed that primary hepatic
venous thrombosis (classical BCS) and thrombosis
of the IVC at the level of the IVC were two separate
syndromes. Recent studies continue to suggest a clear
division within the definition of “primary BCS” based on
[4,10]
the location of the obstructive lesion
. Obstruction of
the hepatic veins or “classical BCS” appears to be more
common in Western patient populations and usually has
[11,12]
a known etiology
, acute onset of symptoms, and
a greater severity of symptoms requiring a different
therapeutic approach than obstruction of the IVC at
[4,13,14]
the level of the hepatic veins
. In comparison with
“classical BCS”, hepatic vena cava (HVC)-BCS appears
to be more common in East Asian patient populations,
and is more often idiopathic or due to membranous
obstruction. HVC-BCS more commonly presents with a
chronic onset of less severe symptoms, thus requiring
[15]
a different therapeutic approach than “classical BCS” .
The location, size, and chronicity is clinically important
as it dictates the patient’s symptoms and directs the
[10]
therapeutic approach for patient management .

wall varices. Myeloproliferative neoplasms (MPN) are the
most common etiology of classical BCS (16%-62%) with
the JAK2V617-F mutation found in 26%-52%. In HVCBCS, MPN are found in 4%-5%, and the JAK2V617-F
mutation in 2%-5%. Classical BCS responds well to
st
medical management alone and 1 line management of
HVC-BCS involves percutaneous recanalization, with few
managed with medical management alone.
CONCLUSION: Systematic review of recent data
suggests that classical BCS and HVC-BCS may be two
clinically different disorders that involve the disruption
of hepatic venous outflow.
Key words: Budd-Chiari; Hepatic vein outflow tract
obstruction; Membranous obstruction of the inferior
vena cava; Obliterative hepatocavopathy; Hepatic vein
thrombosis
© The Author(s) 2016. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: With improved diagnostic methods, the termi
nology for Budd-Chiari syndrome (BCS) has expanded
discordantly. This systematic review discusses recent
population studies of BCS and proposes the delineation
of two clinically unique syndromes.
Shin N, Kim YH, Xu H, Shi HB, Zhang QQ, Colon Pons JP,
Kim D, Xu Y, Wu FY, Han S, Lee BB, Li LS. Redefining
Budd-Chiari syndrome: A systematic review. World J Hepatol
2016; 8(16): 691-702 Available from: URL: http://www.
wjgnet.com/1948-5182/full/v8/i16/691.htm DOI: http://dx.doi.
org/10.4254/wjh.v8.i16.691

INTRODUCTION
Budd-Chiari syndrome (BCS) was originally described as
a rare vascular disorder that encompasses an array of
symptoms due to obstruction of hepatic blood outflow
at the level of the hepatic veins or hepatic portion of the
[1]
inferior vena cava (IVC) . The symptoms resulting
from this type of occlusion of the hepatic outflow, “classi
[2,3]
cal BCS”, were first described by Budd
in 1845 and
later by Hans Chiari in 1899. With the advancement of
diagnostic and therapeutic techniques, providers have
[4]
expanded upon these initial characterizations . Histori
cally, identifying the precise location of the obstruction
was challenging, leading to the propagation of simplified
descriptions. The precise location of the obstruction(s)
is however clinically and prognostically significant. As
[5]
Valla proposed, the clinical manifestations of BCS
(the selective group of symptoms that characterize
the syndrome) can be explained by the location of the
obstruction: Within the hepatic veins vs within the IVC
at the level of the hepatic ostia. Over time, in order to
incorporate novel and more detailed findings associated
with BCS, the lexicon has evolved discordantly. The

WJH|www.wjgnet.com

Precedence

Historically, hepatic sinusoidal obstruction syndrome
(SOS) or veno-occlusive disease was included under the
[1,16-18]
general term BCS
. SOS is specifically defined as
obstruction of the sinusoids or hepatic veins resulting
from sinusoidal wall injury. Several distinct clinical
characteristics differentiate SOS from BCS and the
two conditions are now considered separate entities
as the distinct etiology and pathophysiology of SOS
necessitates different management strategies. SOS is
caused by pyrrolizidine alkaloid toxicity, whereas BCS
is caused by multifactorial prothrombotic condition(s)
[18]
or membranous obstruction of the IVC and/or HV .
Pyrrolizidine alkaloids include over 150 compounds that
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[18]

occur naturally in several plant families . Historically,
they were ingested in indigenous herbal teas or
inadvertently via crop contamination in developing
countries. Currently, pyrrolizidine alkaloids are used
as myeloablative regimens for patients preparing for
hematopoietic stem cell transplantation. Thus, SOS
almost exclusively affects hematopoietic stem cell
transplant patients, while BCS can affect a wide range
[9]
of patient populations . Clinically, both SOS and BCS
can present with abdominal pain, portal hypertension,
jaundice, and non-cirrhotic ascites. Management of
SOS is challenging and involves preventive measures
(avoiding pyrrolizidine alkaloids in susceptible patients)
and a few interventional therapeutic options (defibrotide,
heparin, shunt procedures, etc.). In contrast, manage
ment of BCS ranges from medical management (e.g.,
anticoagulation) to interventional procedures (angio
[19]
plasty, stents, shunt procedures, etc.) .
Due to the low incidence of “BCS” in many countries,
published data tended to include only small case series.
Recently, there have been an increasing number of
larger observational studies (both retrospective and
prospective), particularly from Asia (China) and Europe.
Advancing imaging technologies, such as computed
tomography (CT) angiography, magnetic resonance (MR)
angiography, Doppler ultrasound (US), and angiography
have allowed for better identification and delineation of
this disease. This may signal the start of prospective,
randomized, controlled therapeutic trials which can diffe
rentiate classical BCS from HVC-BCS and their manage
ment strategies. Other investigators have suggested
various novel classification systems, including those
[8-16]
that forego the eponym “Budd-Chiari” altogether
.
However, given that both classical and HVC-BCS reflect
an obstruction in hepatic venous outflow, we propose a
clarification of the general BCS term into classical BCS
and HVC-BCS.

studies such as US, CT, MR imaging, or venography)
and to explicitly describe inclusion and exclusion criteria
to ensure the focus on primary BCS (vs secondary
BCS). For multiple studies published from the same
institution(s) within a close time frame, we reviewed
years of subject recruitment, methodology specifics, and
results. In addition, we also investigated if there were
possible overlapping subjects and/or results. Only the
most recent eligible studies were included in this review,
unless distinctly specific and separate findings were
[20,21]
previously reported
.
Of the 587 studies, the following were excluded: 390
were missing key clinical information (e.g., clear inclusion
and exclusion criteria) or focused on a subpopulation
within the BCS population (e.g., only BCS patients
requiring liver transplantation, etc.); 71 studies were
not limited to primary BCS; 86 studies were not mainly
focused on BCS, but rather broader topics associated
with BCS (e.g., causes of liver transplantation, etc.); 17
studies were older versions of recently published subject
populations with similar study aims. Twenty-six studies
were included for analysis in this review (Figure 1).

RESULTS
Epidemiology

Many observational studies have recently been published
on “BCS” (Table 1). For clarity and compromise, only
the terms classical BCS and HVC-BCS will be used
to differentiate between the two types of BCS in this
review. After considering the location of the obstruction
and clinical manifestations of the subjects, studies were
grouped as majority-classical BCS or majority-HVC-BCS
studies in Table 1. It has previously been suspected
that classical BCS is more likely to present in women
[9,13]
with a pure hepatic vein obstruction
. This review
continues to support this observation as 13 of the 14
included studies reported a higher incidence of classical
BCS in women; 55%-76% of the reported population
is female. In addition, recent studies continue to report
pure obstruction in the majority of cases 49%-85%.
Most studies reported pure hepatic vein obstruction in
> 71% of patients (Table 1). Compared with classical
BCS, HVC-BCS is more common in men (51%-66%)
and more likely to present with an IVC obstruction with
or without involvement of the HVs (69%-100%) (Table
1).

MATERIALS AND METHODS
A systematic literature search yielded 818 results in the
PubMed database; 428 in the Scopus database; 18 in
the CINAHL database; and 17 in the Cochrane database.
All duplicates were removed. After 18 additional studies
(from the references within included studies) were
added, 1178 study abstracts were screened. Of these,
591 were excluded because of the publication type and/
or subject (reviews, case reports including less than 20
patients, non-human studies, or studies not on BCS (e.g.,
Chiari malformations, acute liver failure, etc.). The full
text articles of the remaining 587 studies were acquired
to determine eligibility.

Clinical manifestations in classical BCS vs HVC-BCS

Classical BCS typically presents with an acute onset of
symptoms with most studies reporting the duration of
symptoms < 6 mo (Table 2) with 60%-85% of patients
having an acute presentation of symptoms; however,
one study from Egypt designated 80% of their 94 patients
as chronic, but the definitions of chronic vs acute were
[22]
not explicitly delineated . Classical BCS typically
presents with abdominal pain (45%-86% of patients),
ascites (76%-100%), and hepatomegaly (43%-83%)
(Table 2). In comparison, HVC-BCS typically presents

Inclusion criteria

Clinical trials and observational studies (prospective
or retrospective) conducted in predominantly adult
subjects with primary BCS were included in this study.
All of the included studies needed to explicitly delineate
diagnostic methods for BCS (namely standard imaging
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Table 1 Epidemiology of classical Budd-Chiari syndrome and hepatic vena cava-Budd Chiari syndrome
Ref.

Country

Janssen et al[27]
Perelló et al[40]
Colaizzo et al[30]
Darwish Murad et al[24]
Xavier et al[31]
Sakr et al[22]
Deepak et al[29]
Rautou et al[37]
Raszeja-Wyszomirska et al[45]
Westbrook et al[32]
D’Amico et al[34]
Harmanci et al[42]
Nozari et al[47]
Pavri et al[38]
Faraoun et al[25]
De et al[23]
Xu et al[41]
Ebrahimi et al[46]
Park et al[51]
Qi et al[35]
Cheng et al[13]
Qi et al[36]
Zhou et al[26]
Gao et al[49]
R
NR

Publication

Recruitment

date

years

2000
2002
2008
2009
2010
2011
2011
2011
2012
2012
2013
2013
2013
2014
2015
2001
2004
2011
2012
2013
2013
2014
2014
2015

1984-1997
1990-2000
1997-2006
2003-2005
2000-2008
2009-2011
2006-2009
1995-2005
2004-2011
1985-2008
2005-2011
1989-2011
1989-2012
2008-2013
2008-2012
1992-1998
1983-2003
2002-2008
1988-2008
1999-2011
2010-2011
2012-2012
2006-2010
2008-2012

The Netherlands
Spain
Italy
Europe
Brazil
Egypt
India
France
Poland
United Kingdom
Italy
Turkey
Iran
United States
Algeria
India
China
Iran
South Korea
China
China
China
China
China

n

Age
(median)

43
21
32
163
31
94
20
94
20
66
31
62
55
47
176
40
1360
21
67
169
145
25
338
98
373

Gender

Location of obstruction (%)

M (%)

F (%)

40
361
35
38
33
28.81
36.6
381
38
36
46
42.81
291
42.4
331
35.21
33.21
421
47
38.31
46
35.71
41.71

16 (37)
5 (24)
9 (28)
70 (43)
11 (35)
36 (38)
14 (70)
34 (36)
9 (45)
27 (41)
14 (45)
26 (42)
22 (40)
16 (34)
75 (43)
26 (65)
833 (61)
11 (52)
34 (51)
66 (52)
90 (6)
14 (56)
209 (62)

27 (63)
16 (76)
23 (72)
93 (57)
20 (65)
58 (62)
6 (30)
60 (64)
11 (55)
39 (59)
17 (55)
36 (58)
33 (60)
31 (66)
101 (57)
14 (35)
527 (39)
10 (48)
33 (49)
61 (48)
55 (38)
11 (44)
129 (38)

HV

IVC

125 (71)
N/A
2 (0)
6 (29)
5 (7)
53 (31)
45 (31)
4 (16)
45 (13)

363
453

62 (63)
193 (52)

36 (37)
180 (48)

31 (32)
82 (22)

Both

17 (81)

0 (0)

4 (19)

80 (49)

4 (2)

79 (48)

70 (74)
17 (85)
73 (78)

3 (3)
1 (5)

16 (17)
2 (10)
13 (14)

35 (56)

8 (14)

19 (30)

0 (0)
51 (29)
23 (72)
9 (28)
1358 (100)2
12 (57)
3 (14)
56 (84)
6 (9)
20 (12)
96 (57)
8 (6)
92 (63)
0 (0)
21 (84)
8 (2)
285 (84)
26 (27)
169 (45)

41 (42)
122 (33)

1

Mean values; 2No differentiation between IVC alone vs both IVC and hepatic vein; 3Provided median ages for the two groups separately. R: Recurrence of
disease, NR: Non-recurrence of the disease; HV: Hepatic vein; IVC: Inferior vena cava; M: Male; F: Female; N/A: Not available.

1281 studies (818 PubMed, 428
1
1
1
Scopus , 18 CINAHL , 17 Cochrane )

18 records from
references within studies

After duplicates removed: 1178

1178 screened

591 excluded

2

587 full-text articles
assessed for eligibility

390 missing key clinical/study design information
3
86 not focused on BCS
71 not primary BCS
17 previously published subject publication

26 studied included in analysis

Figure 1 Flow diagram of studies selection. 1Searches conducted with MEDLINE results removed; 2Studies missing key clinical information including clear
inclusion and exclusion criteria, clear diagnostic parameters, etc., and studies that investigated subpopulations (e.g., BCS patients requiring liver transplantation, BCS
patients without MPN, etc.); 3Studies focused on other categories (e.g., causes of liver failure). BCS: Budd-Chiari syndrome; MPN: Myeloproliferative neoplasms.
[13,23]

BCS (Table 2)
. The severity of disease depends
upon both the extent of disease (the number of occluded
vessels, complete or incomplete occlusion), the presence
of associated symptoms (refractory ascites, portal vein
thrombosis, etc.), and the chronicity of symptoms.
Patients with the chronic variation of disease generally
have several milder episodes of vague symptoms (abdo
minal pain or leg swelling), providing sufficient time for

with chronic onset of symptoms (75%-86% of patients),
with an average duration of symptoms prior to diagnosis
ranging from 44-96 mo. Nine to seventy percent of
patients (most studies reporting < 29%) with HVC-BCS
present with abdominal pain, 32%-90% with ascites,
and 28%-95% with hepatomegaly. Splenomegaly,
abdominal wall varices, lower extremity varices, and
discoloration are more commonly associated with HVC-
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10 (48)
1 (5)
1 (5)
1.42

Spain
21
18 (86)
18 (86)
9 (43)

15 (9)
8 (5)
<1
23 (14)
138 (85)

45 (58)1

Europe
163
99 (61)
135 (83)
109 (67)
85 (52)

et al [24]

et al [40]

75 (80)3
18 (19)

46 (49)
36 (38)
29 (31)
15 (16)

Egypt
94
78 (83)
80 (85)
78 (83)
48 (51)
39 (41)

et al [22]

Sakr

Classical BCS

7 (7)
5 (25)

20 (100)

73 (78)

53 (56)

Poland
20

et al [45]

Raszeja-Wyszomirska

France
94

et al [46]

Rautou

32 (48)

United Kingdom
66
36 (55)
57 (87)

et al [32]

Westbrook

7 (23)

18 (58)

Italy
31

et al [34]

D'Amico

1-6
25 (40)
37 (60)

28 (45)

Sweden
62
28 (45)

et al [42]

Harmanci

6
21 (38)
34 (62)

10 (18)

Iran
55
33 (60)
42 (76)
33 (60)
19 (34)

et al [47]

Nozari

30 (75)

6 (15)

28 (70)
15 (38)

India
40
28 (70)
30 (75)
38 (95)
26 (65)
38 (95)

et al [23]

De

162 (12)

116 (9)

China
1360
122 (9)
914 (67)
1124 (83)
683 (50)
821 (60)

et al [41]

Xu

12 (57)

14 (67)

Iran
21
5 (29)
19 (90)
8 (38)

et al [46]

1 (1)
25 (15)
44

86 (51)

50 (30)

95 (56)

China
169

et al [35]

Qi

HVC-BCS
Ebrahimi

Cheng

31 (21)
96
125 (86)
20 (14)

76 (52)

China
145
30 (21)
77 (53)
40 (28)
113 (78)
73 (50)

et al [13]

[49]

76 (78)
61 (62)

224 (60)
165 (44)

R vs NR
China
98
373

Gao et al

695
[5,24]

. In contrast, acute onset and/or significant obstruction (e.g., complete occlusion of several hepatic veins) increases the risk of acute

[1]

Uncovering the etiology of BCS can be challenging. In classical BCS, however, thrombotic risk factors are consistently identified in the majority of patients . Findings reported
in recent studies continue to report myeloproliferative neoplasms [MPN, previously called myeloproliferative disorders (MPD)] as the most common etiology of classical BCS;
9 out of 14 studies found that it is the most common cause of classical BCS affecting 16%-62% of patients, with many reporting between 41%-62% (Table 4). The most
commonly observed MPNs include polycythemia vera (PV) and essential thrombocythemia (ET) found in 18%-43% and 6%-14% of classical BCS patients, respectively. The
[27-34]
JAK2V617-F mutation is a sensitive marker for MPN and has been observed in 26%-52% of patients with classical BCS
. In contrast, in several large Chinese studies,

Etiology

Patients with classical BCS typically have an obstructing thrombus within the hepatic veins (Figure 2)
. In contrast, patients with HVC-BCS typically have a membranous
[24]
or segmental obstruction involving the IVC
(proximal to the ostia of the hepatic veins), but the obstruction can extend into, or secondarily involve the hepatic veins
themselves (Figure 3). Observational studies continue to reflect this difference between classical BCS and HVC-BCS patients; several studies from Europe to northern Africa
consistently describe a thrombotic obstruction (87%-95%) limited to the hepatic veins (49%-85%) and rarely describe a membranous obstruction (1%-5%) located at only
the IVC (0%-14%). However, in HVC-BCS patients, many studies report a membranous obstruction (30%-61%) only located at the IVC (57%-72%) or both the IVC and HV
[24-26]
(63%-84%). Obstructions in HVC-BCS patients are not commonly isolated in the hepatic veins (0%-31%)
. The development of collateral circulation takes time; given
that the chronic form of BCS is more commonly associated with HVC-BCS, it is not surprising that the development of collateral circulation is more typical with HVC-BCS
patients (63%-65%) than with classical BCS patients (Table 3).

Obstruction characteristics

the development of collateral vessels
hepatic failure.

[13,24]

77 patients underwent EGD; 2Mean, not median. Most studies reported median duration of symptoms in months; when the median was not available, the mean is reported; 3No definition of “chronic” was provided. BCS: BuddChiari syndrome; HVC: Hepatic vena cava; R: Recurrence of BCS; NR: Non-recurrence of BCS.

1

Country
n (%)
Abdominal pain
Ascites
Hepatomegaly
Splenomegaly
Abdominal wall varices
Esophageal varices
Lower extremity edema
Jaundice
Encephalopathy
Bleeding episodes
Duration of symptoms
Chronic, > 6 mo
Acute, < 6 mo

Darwish Murad

Perelló

Table 2 Signs and symptoms in classical Budd-Chiari syndrome and hepatic vena cava-Budd Chiari syndrome
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IVC
MHV

IVC
LHV

LHV

RHV

RHV

Figure 2 Classical Budd-Chiari syndrome - Occlusions are within the
hepatic veins themselves and usually thrombi. RHV: Right hepatic vein;
MHV: Middle hepatic vein; LHV: Left hepatic vein; IVC: Inferior vena cava.

Figure 3 Hepatic vena cava-Budd Chiari syndrome - Occlusions are thin
or thick (membranous or segmental) and within the inferior vena cava
and occlusion can extend into the hepatic veins and generally involve the
ostia to the inferior vena cava. RHV: Right hepatic vein; MHV: Middle hepatic
vein; LHV: Left hepatic vein; IVC: Inferior vena cava.

MPN were only found in 4%-5% of patients (PV in 2%
and ET in 1%-2%) and the JAK2V617-F mutation in
only 0%-5% of patients diagnosed with primary HVC[13,35,36]
BCS (Table 4)
.
Hereditary prothrombotic conditions such as factor
Ⅴ Leiden mutation (FVL), prothrombin (PT) 20210A
mutation, protein C deficiency (PCD), protein S defi
ciency (PSD), antithrombin deficiency (ATD), plasmi
nogen activator inhibitor [PAI-1 (4G-4G)], and the
5,10-methlenetetrahydrofolate reductase enzyme
mutation (MTHFRC677T) often also play a significant
role in the development of classical BCS. Following
MPNs, the FVL mutation is the second most common
cause of classical BCS and was found in 2%-53% of
patients. Thrombophilic conditions also may contribute
to the development of classical BCS. Mutations in PT
were found in 2%-8% of patients with classical BCS vs
0% of patients with HVC-BCS. PCD, PSD, and ATD were
found in 3%-26%, 1%-9% and 3%-15% of patients
with classical BCS, respectively, vs 0% of patients with
HVC-BCS (Table 4). Interestingly, this pattern is not
apparent with MTHFRC677T mutations; these mutations
were found in 26%-52% of patients with classical
BCS and 71%-72% of patients with HVC-BCS. Less
common but established prothrombotic or associated
conditions further include antiphospholipid antibodies
(classical BCS: 3%-29% vs HVC-BCS: 0%-17%),
hyperhomocysteinemia (10%-18% vs 21%-50%), and
paroxysmal nocturnal hemoglobinuria (0%-19% vs
0%-4%). Several systemic conditions (classical BCS:
5%-24% vs HVC-BCS: 1%-19%) including connective
tissue disorders such as systemic lupus erythematosus
(5%-12% vs 1%) are generally associated more
frequently with classical BCS. Hormonal factors such
as oral contraceptives, pregnancy, or puerperium can
also increase the risk of thrombosis as can local insults
such as recent surgery. Of these numerous differences
between classical BCS and HVC-BCS, one consistent
difference is the greater influence of hormonal changes
(be it oral contraceptive use or pregnancy) in classical
BCS patients (4%-52% of the female population) (Table
[29,37-39]
4)
.
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MHV

Membranous obstruction of the IVC (and/or HV)
is consistently listed as the etiology of a significant
number of HVC-BCS patients (52%-61%). In classical
BCS patients, membranous obstruction is rare (1%)
or rarely explicitly delineated, except in one study
of 23 consecutive patients diagnosed with BCS in
Germany where 5 patients (22%) were found to have
[24]
a membranous obstruction of the IVC . Furthermore,
despite comprehensive work-up, an etiologic factor is
often not identified in HVC-BCS patients (19%-29% vs
classical BCS: 5%-30%) (Table 4).
Data from recent studies continues to support the
possibility of two different types of BCS with separate
etiologies: Classical BCS, where thrombophilic risk
factors and often multiple concomitant factors are
common vs HVC-BCS, where thrombophilic risk factors
are uncommon, but membranous obstruction and
idiopathic hepatic venous outflow obstruction are more
common.

Management and outcomes

Treatment and prognosis of BCS depends on a few key
factors: Acuity of symptoms, location and extent of
[24]
[11]
the obstruction, and etiology . In 2013, Seijo et al
outlined a step-wise management approach for BCS
patients from the analysis of the extended follow-up
data of 157 patients from 9 European countries. This
management approach starts with medical management
alone (e.g., salt-restriction, anticoagulation, diuretics),
including concomitant management of any underlying
etiological processes. Diagnostic work-up for classical
BCS patients generally includes hematologic work-up
[29-31,33]
for MPN, JAK2V617F mutation screening for MPN
,
[28]
testing for FVL mutation , and the aforementioned
thrombophilic risk factors. In addition, some studies
recommend continued monitoring of JAK2-mutation[5,9,33]
. In general, the
positive-patients for occult MPNs
medical management of classical BCS patients involves
anticoagulation and ascites management with diuretics.
Patients with MPN require additional aspirin and cyto
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70 (74)
3 (3)
16 (17)
DNS
2 (1)

80 (49)
4 (2)
79 (48)
DNS

Egypt
94

[22]

DNS
DNS

17 (85)
1 (5)
2 (10)

India
20

Deepak et al

Classical BCS
Sakr et al

17 (81)
0 (0)
4 (19)
20 (95)
3 (14)
1 (5)

[24]

Europe
163

Darwish Murad et al

Spain
21

[40]

[29]

35 (56)
8 (14)
19 (30)
54 (87)
27 (44)
DNS

Turkey
62

Harmanci et al

[42]

125 (71)
0 (0)
51 (29)
170 (97)
DNS
DNS

Algeria
176

Faraoun et al

[25]

[23]

12 (30)

N/A
23 (72)
9 (28)

India
40

De et al

[41]

DNS
123 (9)
717 (53)

2 (0)
1358 (100)

China
1360

Xu et al

11 (52)

6 (29)
12 (57)
3 (14)

Iran
21

[46]

HVC-BCS
Ebrahimi et al

89 (61)
92 (63)
36 (25)1

45 (31)
8 (6)
92 (63)
15 (10)

China
145

Cheng et al

[13]

[26]

220 (65)
79 (23)

45 (13)
8 (2)
285 (84)

China
338

Zhou et al

697

[4,5]

This systematic literature review highlights the numerous differences between classical BCS and HVC-BCS. Despite the growing cognizance of this difference

DISCUSSION
and despite

reductive medications (e.g., hydroxyurea). Patients with autoimmune diseases (e.g., antiphospholipid syndrome, Behçet’s disease, etc.) require additional corticosteroids
and/or immunosuppressive drugs. If patients fail medical management, therapy is then escalated to minimally invasive procedures including percutaneous transluminal
angioplasty (PTA) and/or thrombolysis. If patients fail to respond to these measures, developing refractory ascites, variceal bleeding, or liver failure, they are then treated
[11,40,41]
[32]
with transjugular intrahepatic portosystemic shunt (TIPS) or other shunt operations
, with liver transplantation as a final option . Such an approach appears to result
[11]
in good long-term survival (Table 5) .
Recent studies continue to support that medical management alone can be appropriate for classical BCS patients; 33%-54% of the classical BCS patients treated with
medical management alone have good outcomes. In contrast, only 0%-7% of HVC-BCS patients are treated with medical management alone. While both classical and HVCBCS patients benefit from interventional therapy, the specific interventions are different. Classical BCS patients commonly undergo TIPS (classical BCS: 4%-62% vs HVCBCS: 1%-4.5%) and liver transplantation (9%-55% vs 0%-1%). In a study of 62 predominantly classical BCS patients from Turkey, none of the patients underwent liver
[42]
transplantations, but that was due to a lack of donor availability . In contrast, first line management of HVC-BCS with percutaneous re-canalization (with or without stent
[43]
[44]
deployment) has good outcomes . In one large study from China, Han et al found that all 187 consecutively diagnosed primary BCS patients at one institution were
eligible for percutaneous recanalization, regardless of the location of the obstruction. Recent studies report that HVC-BCS patients undergo PTA more frequently compared to
classical BCS patients (HVC-BCS: 43%-92% vs classical BCS: 3%-18%). After percutaneous recanalization, patients are anticoagulated with an international normalized ratio
[44]
goal of 2-3 for a minimum of 6-8 mo per standard post-endovascular intervention management guidelines .
Median follow-up for both classical BCS and HVC-BCS patients were similar (classical BCS: 17-58 mo and HVC-BCS: 12-103 mo). Both groups of patients fared well
with their respective management strategies. One-year and five-year survival was 79%-96% and 56%-79% among classical BCS patients, respectively. One-year and
five-year survival for HVC-BCS patients was 67%-99% and 75%-86%, respectively (Table 5). Poor prognostic factors for classical BCS patients include: Severe BCS (e.g.,
[37,38]
ascites requiring diuretics or paracentesis, pleural effusion, higher Clichey Prognositc index score), older age, cirrhosis at diagnosis of BCS, and chronic kidney disease
.
[23]
Development of cirrhosis or hepatocellular carcinoma (HCC) are poor prognostic factors for HVC-BCS patients .

Described as “benign nodules”, not benign regenerative nodules. DNS: Study mentions generally, but, does not provide specific counts; BCS: Budd-Chiari syndrome; HV: Hepatic vein; HVC: Hepatic vena cava; IVC: Inferior
vena cava.

1

Country
n (%)
Obstruction location
HV only
IVC only
Both HV and IVC
HV thrombosis
IVC thrombosis
IVC web/membrane
Collateral circulation
Benign regenerative nodules

Perelló et al

Table 3 Obstruction characteristics: Location, type, and associated findings
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6 (19)
1 (3)

1 (3)
1 (4) (OC)3

5 (15)
2 (8)
2 (7)2
2 (7)2

2 (9)
13 (52) (OC)3

2 (5)

32
13 (41)

Italy

al [30]

Colaizzo et

40
13 (33)
7 (41)

Netherlands

al [39]

Smalberg et

7 (35)

3 (10)
1 (3)

31
5 (16)
8 (26)

Brazil

et al [31]

Xavier

8 (9)

12 (13)7

2 (2)
19 (33)

31 (52)6

34 (53)5
3 (5)6
4 (4)
1 (1)
4 (4)

18 (29)4

94

Egypt

al [22]

Sakr et

2 (10)
1 (5)

2 (10)
1 (5)
3 (15)

5 (25)

20
8 (40)
8 (40)

India

et al [29]

Deepak

6 (30)

1 (5)

3 (15)

1 (5)

20
8 (40)

Poland

et al [45]

et al [32]

et al [34]

al [11]

et al [42]

3 (5)7

0 (0)

1 (2)
1 (2)
2 (3)

United
Kingdom
66
37 (56)
34 (52)

2 (6)

4 (24)

17 (55)
8 (26)

9 (29)
1 (3)

31
17 (55)

Italy

37 (24)

6 (10)

8 (13)7

1 (2)
4 (11)

19 (39)

15 (30)
1 (2)
16 (31)
5 (10)
6 (15)

28 (18)
12 (8)
19 (12)
5 (3)
5 (3)
3 (2)
4 (3)

29 (18)
15 (10)
35 (39)

62
19 (31)

Turkey

157
52 (33)

Europe

Raszeja-Wyszomirska Westbrook D'Amico Seijo et Harmanci

Classical BCS

8 (12)
21 (35) (OC)3

15 (19)
6 (8)
6 (12)
5 (9)
3 (4)

94
51 (59)

France

al [37]

Rautou et

5 (9)
autoimmune
10 (18)

3 (9)

12 (20)
3 (6)
3 (6)

10 (18)

55
9 (16)

Iran

al [47]

Nozari et

al [38]

et al [46]

3 (6)
2 (6)
(OC)3

2 (4)
1 (2)

14 (30)
3 (6)
4 (9)

United
States
47

6 (29)
11 (52)

4 (19)8

21

Iran

145
5 (5)10
5 (5)10
2 (2)10
2 (2)10
0 (0)11
0 (0)11
0 (0)12
0 (0)12
0 (0)12

0 (0)
0 (0)

0 (0)

25

China China

2 (1)

28 (19)
89 (61)
6 (4)
60 (41)
23 (16)

1 (1)

96 (71)
18 (72)
64 (50) 30 (21)
1 (1)
0 (0)13 1 (4)
2 (4)

169
7 (4)9
4 (2)
3 (2)
1 (1)
0 (0)
0 (0)

China

Cheng Qi et
al [35] et al [13] al [36]

HVC-BCS
Pavri et Ebrahimi Qi et

the abundance of recent publications on BCS, there is still a paucity of large, randomized clinical trials with regard to classical and/or HVC-BCS. The vast heterogeneity of
these recent publications with regards to recruitment of solely primary vs secondary BCS, of solely classical or HVC-BCS, and of patients who have not previously been
recruited and described, may lead to disparate and skewed patient populations that preclude certain data analyses and conclusions. Thus, this review specifically sought out
studies that recruited BCS subjects that were representative of the indigenous BCS patient population. We attempted to minimize selection bias by excluding studies that
focused on a particular subgroup of patients (e.g., BCS patients requiring liver transplantation, exclusion of patients with specific previously diagnosed etiologies, etc.). We
also attempted to minimize multiple representations of the same patient population by comparing recruitment periods from studies that were similar in geographic location
(institution, city, and country) or similar in authorship. The selected studies thereby provide an unadulterated presentation of the differences between classical vs HVC-BCS
according to geography, patient demographics, location of obstruction, and treatment strategies and outcomes. The examination of these differences is important as they
impact the diagnostic work-up and the therapeutic management strategies for individual patients and healthcare communities alike.

7

Percentage of total female patients; 2Patients on anticoagulation were not tested; 3Number of women on OC only, no specific information on number of pregnant women; 4Out of 62 tested; 5Out of 64 tested; 6Out of 60 tested;
Mainly Behcet’s disease; 8Behcet’s disease (2), Hepatitis C (1), Leukemia (1); 92 of these 7 patients were diagnosed with latent MPN; 10In this study, most (105 patients), but, not all were tested; percentages are out of 105; 11Out of 96
patients were tested; 12Out of 80 patients tested; 13Out of 83 patients tested. BCS: Budd-Chiari syndrome; HV: Hepatic vein; HVC: Hepatic vena cava; ET: Essential thrombocythemia; PNH: Paroxysmal nocturnal hemoglobinuria;
OCP: Oral contraception; MOVC: Membranous obstruction of IVC; NAD: No associated disease/etiology found; MPN: Myeloproliferative neoplasms; FVL: Factor Ⅴ Leiden mutation; HH: Hyperhomocysteinemia.

1

Spain

n (%)
21
MPN (%)
13 (62)
JAK2V617-F
N/A
PV
9 (43)
ET
3 (14)
FVL
2 (10)
PT 20210A
Protein C deficiency
Protein S deficiency
AT deficiency
PAI-1 (4G-4G)
MTHFRC677T
HH
PNH
4 (19)
OCP, pregnancy,
or puerperium1
Systemic diseases
or local factors
NAD/idiopathic
1 (5)
Web/membrane
MOVC
MOVC + HV
1 (5)
MOHV

Country

et al [40]

Perelló

Table 4 Risk factors and/or etiologies of classical Budd-Chiari syndrome and hepatic vena cava-Budd Chiari syndrome
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2 (10)
13 (62)

1 (5)

5813
3813
7 (100) 12 (86)

PTA
Shunt operation
TIPS2
Liver transplantation

Median follow-up (in months)
Survival
At 1 yr
At 5 yr
Mortality

74 (79)

43
74 (79)

28 (30)
15 (16)

17 (18)

France
94
94 (100)

al [37]

Rautou et

17
15 (75)
80%

2 (10)
10 (50)

Poland
20
20 (100)

et al [45]

Seijo et al

[11]

25.212
96%

88%
56%

4 (6)
0 (0)8

95 (73)

50
95 (73)

62 (39)3
204 (13)

Europe
157
139 (89)
69 (54)
49 (71) alive
88 (56)
72 (82) alive
2 (3) in IVC 22 (14)

Turkey
62
61 (98)

al [42]

Harmanci et

40-739

36 (55)

32 (48.5)6

34 (52)5

United Kingdom
66
61 (92)

[32]

Classical BCS
Raszeja-Wyszomirska Westbrook et al

[38]

65 mo10

2 (4)
2 (4)
5 (9)

10 (18)

32
37 (79)
37 (79)

21 (45)
8 (17)

Iran
United States
55
47
55 (100)
≥ 40 (85)

al [47]

Nozari et Pavri et al

75%
1011

56

23 (58)

23 (58)

India
40

al [23]

De et

[41]

81.6

0 (0)

330 (24)

1360 (100)
1318 alive

0 (0)

China
1360

Xu et al

67%7

9 (43)
3 (14)

9 (43)

Iran
21
12 (57)

et al [46]

HVC-BCS
[51]

86%

103

27 (40)
4 (5.9)
3 (4.5)

South Korea
67
32 (48)

Ebrahimi Park et al

2 (1)

99%

12
0 (0)12
2 (1)12
12

134 (92)

141 (97)

4 (3)

China
145

al [13]

Cheng et

401 (94)

19

440 (93)

31 (7)

China
471

al [49]

Gao et

699

Differentiation between classical and HVC-BCS is important because it dictates what constitutes comprehensive and appropriate diagnostic strategies. Given the likelihood
of multiple pro-thrombotic risk factors contributing to the development of classical BCS, recommendations for extensive routine work-up for multiple possible etiologies
[42,45]
[5,9,24,31]
include testing for MPN; JAK2V617F mutation screening for MPN
; continued monitoring of JAK2-mutation-positive-patients for occult MPN
; further testing for TET2
[32]
[28]
[24]
mutation when the JAK2 screening is negative ; FVL mutation ; PT 20210A mutation; protein C and S deficiencies; AT deficiency; PAI-1 and MTHFRC677T mutations .
Since more than one thrombophilic condition often manifests in classical BCS patients, such an extensive work-up is appropriate, but recent data continues to suggest that
[24]
those same recommendations may not be appropriate for HVC-BCS patients . For instance, screening for the JAK2V617F mutation is important for classical BCS patients
[42]
because it has been reported to be a better diagnostic test for MPN when compared to traditional hematologic tests . The JAK2V617F mutation has consistently been found
in a significant number of “idiopathic” cases of classical BCS (although this is not observed in “idiopathic” HVC-BCS). In a study of 41 classical BCS patients from England,
[32]
the JAK2V617F mutation was detected in 58.5% of idiopathic BCS cases . Furthermore, 93% of the patients who later developed latent MPN were positive for the mutation
[33]
suggesting that the JAK2V617F mutation is a highly sensitive marker to detect overt or covert MPN . Given the possible geographic distribution of classical and HVC-BCS
in regions with limited healthcare resources, a clear delineation of standard of care would benefit patients and providers alike. Historically, it has been speculated that there
is association between lower standards of living and HVC-BCS. However, a recent prospective study including 53 consecutive BCS patients from Western India found no
association between socioeconomic status and location of hepatic venous outflow obstruction although, a correlation between living in mud houses and IVC membranous
[28]
obstruction was observed . Therefore, according to this review, balancing the costs of diagnostic work-up for numerous potential genetic or acquired pro-thrombotic factors

Medical management includes anticoagulation, diuretics, and medical treatment of any underlying causes; 2After PTA failed; 3Of the 22 patients who initially were treated with PTA/thrombolytics, 12 subsequently underwent
TIPS and 2 underwent OLT; 4Among the 62 patients who underwent TIPS, 4 subsequently underwent OLT; 5Patients who failed medical management (namely anticoagulation with heparin and warfarin and diuretics) as defined
by persistent transaminitis, resistant ascites or worsening hepatic function) moved on to receive stenting, shunting, or TIPS; 650% success rate (16/32); 7Per study, 7 out of 21 patients died before hospital discharge; 8No patients
underwent liver transplantations due to a lack of donor availability; 9Median follow-up post liver transplantation was 40 mo and median follow-up of patients with MPN was 73 mo; 10Mean survival time was 65 mo; 1110 patients
died by the 5-yr follow-up period; 12At the end of the follow-up period, 2 patients were waiting to receive OLT from another hospital; 13Mean, not median values provided. Interventional therapy includes both endovascular and
surgical procedures. OLT: Orthotopic liver transplant; TIPS: Transjugular intrahepatic portosystemic shunt; PTA: Percutaneous transluminal angioplasty; BCS: Budd-Chiari syndrome; HVC: Hepatic vena cava; IVC: Inferior vena
cava.

1

14 (67)

[40]

Interventional therapy

Country
Spain
n (%)
21
Medical management
21 (100)
Medical management only (%)1 7 (33)

Perelló et al

Table 5 Management and outcomes in classical Budd-Chiari syndrome and hepatic vena cava-Budd Chiari syndrome
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[25,38]

with the actual benefit the patient may gain should be
BCS-type specific.
Treatment and prognosis of BCS depends on a
few key factors: Acuity and severity of the symptoms,
location and the extent of the obstruction, and etiology
[24]
of the obstruction . While anticoagulation (initially
with heparin and chronically with warfarin) is the initial
treatment of choice for both classical BCS and HVC[45]
BCS patients , the expected response and course of
therapy differs dramatically. Classical BCS patients often
present with acute thrombosis of the hepatic veins.
This rapid blockage of hepatic venous outflow precludes
the ability to adapt via the development of collateral
circulation. It is not surprising then that acute fulminant
liver failure (with its sequelae) is more common among
classical BCS patients, thus requiring shunt operations
and liver transplantations more frequently than in
[13]
HVC-BCS patients . In contrast, HVC-BCS patients
generally present with chronic symptoms that may
lead to the transformation of an old thrombus into a
[7,25]
fibrous, membranous obstruction
. Depending on
the thickness and the extent of the obstruction, early
interventional therapy (most commonly PTA with or
without stent deployment), is very effective and thus
[13,46]
more commonly utilized among HVC-BCS patients
.
The thrombotic nature of obstruction observed in
classical BCS may explain why these obstructions are
more susceptible and responsive to medical manage
ment (namely anticoagulation) alone. As noted in
[40]
two long-term follow up studies by Perelló et al
and
[24]
Darwish Murad et al
(with median follow-ups of 58
and 17 mo respectively) of predominantly classical BCS
patients, 33%-44% of patients that were maintained on
medical management alone had good outcomes: 100%
and 44% (at 12 mo), respectively. In both studies,
very few classical BCS patients (5%-9%) required
percutaneous recanalization. In HVC-BCS patients,
the role of anticoagulation is often adjunctive and
temporary; the use of warfarin before angioplasty can
[47]
improve outcomes in patients with IVC obstruction .
Few HVC-BCS patients are managed with medical
management alone because of previously reported poor
[38]
outcomes . In terms of the pathophysiology, Simonetto
[48]
et al
recently used a murine model to demonstrate
that hepatic venous outflow obstruction as seen in
congestive heart failure or veno-occlusive disease led
to liver fibrosis not via an inflammatory pathway, but
via sinusoidal thrombosis and mechanical strain, while
also showing that anticoagulation may have a beneficial
effect in decreasing fibrosis. This aids our understanding
of the mechanism by which BCS and HVC-BCS can
result in fibrosis, and emphasizes the need for relief of
obstruction for proper management. Given the different
presentations and treatment courses of the two entities,
it would be relevant to further study the pathophysiology
of these conditions to better optimize management.
Factors that contribute poor prognosis in classical
BCS include: Increasing age, cirrhosis at the time of
diagnosis, chronic kidney disease, and portal vein

WJH|www.wjgnet.com

. The Child-Pugh and MELD scores also
thrombosis
play an unclear role in terms of practical management,
while asymptomatic patients generally have better
[45,49]
. For HVC-BCS patients, factors that
prognoses
contribute to poor prognosis include the development of
cirrhosis and HCC. Recent studies have suggested that
the risk of developing HCC in HVC-BCS patients (unlike
classical BCS patients) is directly attributable to the
[7]
disease vs Hepatitis B or C infections . Furthermore,
the incidence of developing HCC in HVC-BCS patients
[50,51]
is similar to those of cirrhotic patients
. These
findings suggest that HVC-BCS patients, unlike classic
BCS patients, should be routinely monitored for the
development of HCC. Specific interventions to address
and reduce the high pressure gradient in BCS patients
may reduce the risk of HCC development.
In conclusion, clarification in the terminology descri
bing hepatic venous outflow obstruction would enable
both clinicians and investigators to identify patients with
comparable signs and symptoms, thus enabling the
execution of sound (randomized and controlled) and
separate research studies on pathogenesis, therapy, and
prognosis of what seems to be two different etiologies
of Budd-Chiari syndrome. As summarized in this review,
recent studies continue to support that classical and
HVC-BCS have distinct demographics, characteristics,
etiologies, therapeutic strategies, and prognoses. To
address gaps in knowledge within classical BCS and
HVC-BCS patients, these differences should be acknow
ledged and future research should be performed on
these two conditions separately.
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Background

Budd-Chiari syndrome (BCS) encompasses a wide array of symptoms that
are caused by hepatic venous outflow tract obstruction and has been known
by many different names. While reviewing the recent literature, this paper
delineates the difference between primary hepatic venous thrombosis and
thrombosis of the inferior vena cava (IVC), which have both previously been
referred to as BCS.

Research frontiers

With the influx of new studies examining the wide spectrum of BCS, there
has been a growing argument for the separation of primary hepatic venous
thrombosis (classical BCS) and thrombosis of the IVC at the level of the IVC
(hepatic vena cava-BCS) given the difference in their etiology and management.

Innovations and breakthroughs

This paper supports the clarification of terminology used to describe hepatic
venous outflow obstruction, which will help guide future research and allow for
more specific treatment modalities for this condition.

Applications

The evidence presented helps clinicians to understand the difference in
etiologies of this syndrome and their influence in the management of the
separate entities of this condition.

Terminology

Classical BCS refers to primary hepatic venous thrombosis. HVC-BCS refers to
thrombosis of the IVC at the level of the IVC.
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This review is well organized and comprehensive, has a good clinical message
about BCS, and should be of great interest to the readers.
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